VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 2, 2006, Pages 169-178

  Obayashi, Kyoko ^a   Nakamura, Katsunori ^a   Kawana, Junichi ^a   Ogata, Hiroyasu ^a   Hanada, Kazuhiko ^a   Kurabayashi, Masahiko ^a   Hasegawa, Akira ^a   Yamamoto, Koujirou ^a   Horiuchi, Ryuya ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BUCOLOME; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; VITAMIN K OXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AMINO ACID SUBSTITUTION; ANTICOAGULATION; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CYTOCHROME P450 2C19 GENE; CYTOCHROME P450 2C9 GENE; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRON; JAPAN; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOEMBOLISM; VITAMIN K OXIDE REDUCTASE COMPLEX 1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DNA; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; STEREOISOMERISM; VARIATION (GENETICS); WARFARIN;

EID: 33746765022     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.04.010     Document Type: Article

References (35)

1. Kaminsky L.S., and Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol Ther 73 (1997) 67-74
2. Lee C.R., Goldstein J.A., and Pieper J.A. Cytochrome P450 2C9 polymorphisms. a comprehensive review of the in vitro and human data. Pharmacogenetics 12 (2002) 251-263
3. Daly A.K., and King B.P. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13 (2003) 247-252
4. Takahashi H., and Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40 (2001) 587-603
5. Taube J., Halsall D., and Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
6. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
7. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 (2005) 2285-2293
8. Zhao F., Loke C., Rankin S.C., Guo J.Y., Lee H.S., Wu T.S., et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 76 (2004) 210-219
9. James A.H., Britt R.P., Raskino C.L., and Thompson S.G. Factors affecting the maintenance dose of warfarin. J Clin Pathol 45 (1992) 704-706
10. Absher R.K., Moore M.E., and Parker M.H. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 36 (2002) 1512-1517
11. Fergusson R.J., Eade O.E., Logie A.W., and Gaddie J. A flexible loading dose schedule for warfarin therapy. Scott Med J 32 (1987) 169-171
12. Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., and McLeod H.L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91 (2004) 87-94
13. James A.H., Britt R.P., Raskino C.L., and Thompson S.G. Factors affecting the maintenance dose of warfarin. J Clin Pathol 45 (1992) 704-706
14. Blann A., and Bareford D. Ethnic background is a determinant of average warfarin dose required to maintain the INR between 3.0 and 4.5. J Thromb Haemost 2 (2004) 525-526
15. El Rouby S., Mestres C.A., LaDuca F.M., and Zucker M.L. Racial and ethnic differences in warfarin response. J Heart Valve Dis 13 (2004) 15-21
16. Yu H.C., Chan T.Y., Critchley J.A., and Woo K.S. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 89 (1996) 127-135
17. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
18. D'Andrea G., D'ambrosio R.L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., et al. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
19. Quteineh L., Verstuyft C., Descot C., Dubert L., Robert A., Jaillon P., et al. Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. Thromb Haemost 94 (2005) 690-691
20. Geisen C., Watzka M., Sittinger K., Steffens M., Daugela L., Seifried E., et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94 (2005) 773-779
21. Harrington D.J., Underwood S., Morse C., Shearer M.J., Tuddenham E.G., and Mumford A.D. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 93 (2005) 23-26
22. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements. proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
23. Yuan H.Y., Chen J.J., Lee M.T., Wung J.C., Chen Y.F., Charng M.J., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14 (2005) 1745-1751
24. Matsumoto K., Ishida S., Ueno K., Hashimoto H., Takada M., Tanaka K., et al. The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin. J Clin Pharmacol 41 (2001) 459-464
25. Shikata E., Ieiri I., Ishiguro S., Aono H., Inoue K., Koide T., et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103 (2004) 2630-2635
26. Takahashi H., Kashima T., Kimura S., Muramoto N., Nakahata H., Kubo S., et al. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J Chromatogr B Biomed Sci Appl 701 (1997) 71-80
27. Nasu K., Kubota T., and Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7 (1997) 405-409
28. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269 (1994) 15419-15422
29. de Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46 (1994) 594-598
30. Kimura M., Ieiri I., Mamiya K., Urae A., and Higuchi S. Genetic polymorphism of the cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20 (1998) 243-247
31. Hayashi C. On the prediction of phenomena from qualitative data and the quantification of qualitative data from the mathematico-statistical point of view. Ann Inst Stat Math 3 (1952) 69-98
32. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., et al. Variations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
33. Bodin L., Verstuyft C., Tregouet D.A., Robert A., Dubert L., Funck-Brentano C., et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106 (2005) 135-140
34. Lee S.C., Ng S.S., Oldenburg J., Chong P.Y., Rost S., Guo J.Y., Yap H.L., et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79 (2006) 197-205
35. Yutzey K.E., and Konieczny S.F. Different E-box regulatory sequences are functionally distinct when based within the context of the troponin I enhancer. Nucl Acids Res 20 (1992) 5105-5113